Lung Cancer

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, discusses identifying and treating patients with MET exon 14 skipping mutations in lung cancer.

I have a rare mutation causing my cancer. Are there any others with ROS1 out there?

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of MET exon 14 skipping mutations in lung cancer.

The addition of Avastin (bevacizumab) to chemotherapy after initial therapy did not improve overall survival in patients with surgically resected early-stage non–small cell lung cancer.

My dad was diagnosed with Stage 4 lung cancer in February of 2014. His diagnosis included the BRAF mutation, which is still in the process of being researched for successful treatments.

Kim Statham Ringen, DVM DACVIM (Oncology), a CURE contributor who is currently surviving stage 4 non-small cell lung cancer, discusses the importance of meeting other cancer survivors.

Kim Statham Ringen, DVM DACVIM (Oncology), a CURE contributor who is currently surviving stage 4 non-small cell lung cancer, discusses the stigma of lung cancer.

Most patients younger than age 40 with lung cancer had tumors with mutations that can be targeted with existing therapies, according to a preliminary analysis of data from an ongoing study.

Pneumonitis, a lung inflammation, often appears months after the cancer treatment that sparked it.

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the treatment of patients with lung cancer with brain metastases.

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the progress of immunotherapy as treatment for patients with non-small cell lung cancer.

E-cigarettes, championed by some as a smoking-cessation tool, may actually decrease the likelihood of quitting smoking, according to a recent population-based study of 1,000 smokers published in The American Journal of Public Health.

It's incredible how much personality was squeezed into my mother's 4'10" frame. She was a spitfire. A burst of energy, starting friendly conversations with anyone and everyone she met.

After nearly four years of cancer treatment, I thought I'd experienced all possible types of scanxiety. I was wrong.

The FDA has granted a breakthrough therapy designation to the immunotherapy drug Keytruda (pembrolizumab) for the treatment of patients with non-small cell lung cancer.

Preliminary data from a phase 2 trial demonstrates that a combination of the PARP inhibitor veliparib and chemotherapy benefits patients with squamous cell non-small cell lung cancer.